 B7-H1 Antigen
"B7-H1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION.
| Descriptor ID |
D060890
|
| MeSH Number(s) |
D12.776.467.150.300 D12.776.543.095.300 D23.050.301.285.400 D23.529.168.300
|
| Concept/Terms |
B7-H1 Antigen- B7-H1 Antigen
- Antigen, B7-H1
- B7 H1 Antigen
- Programmed Cell Death 1 Ligand 1
- B7-H1 Immune Costimulatory Protein
- B7 H1 Immune Costimulatory Protein
- PD-L1 Costimulatory Protein
- Costimulatory Protein, PD-L1
- PD L1 Costimulatory Protein
- Programmed Cell Death 1 Ligand 1 Protein
- CD274 Antigen
- Antigen, CD274
- Antigens, CD274
- CD274 Antigens
- B7H1 Immune Costimulatory Protein
|
Below are MeSH descriptors whose meaning is more general than "B7-H1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "B7-H1 Antigen".
This graph shows the total number of publications written about "B7-H1 Antigen" by people in this website by year, and whether "B7-H1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 3 | 3 | | 2009 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2013 | 1 | 1 | 2 | | 2015 | 6 | 0 | 6 | | 2016 | 5 | 4 | 9 | | 2017 | 5 | 2 | 7 | | 2018 | 15 | 3 | 18 | | 2019 | 8 | 9 | 17 | | 2020 | 9 | 6 | 15 | | 2021 | 4 | 7 | 11 | | 2022 | 7 | 11 | 18 | | 2023 | 2 | 11 | 13 | | 2024 | 5 | 5 | 10 | | 2025 | 5 | 6 | 11 | | 2026 | 5 | 3 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "B7-H1 Antigen" by people in Profiles.
-
Horiike A, Wakui H, Sugawara S, Minegishi Y, Tasaka S, Kusumoto S, Sakatani T, Suzuki H, Hosomi Y, Tambo Y, Shimokawa T, Ishida H, Miyauchi E, Naoki K, Fukuhara T, Mura E, Tsurui T, Suzuki R, Iriguchi N, Ishiguro T, Hirasawa Y, Manabe R, Shimokawa M, Ohkuma R, Ariizumi H, Kubota Y, Hamada K, Takenoshita S, Ryu K, Sambe T, Inoue E, Wada S, Yoshimura K, Sagara H, Kobayashi S, Tsunoda T. Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non-Small Cell Lung Cancer with =50% PD-L1 Expression: A Nonrandomized Phase II Trial. Clin Cancer Res. 2026 Oct 15; 32(20):4571-4579.
-
Lingo JJ, Reis R, Koyas A, Voigt E, Zacharias ZR, Allamargot C, Hornick EL, Raygoza Garay JA, Kaemmer CA, Elias EC, Jabbari A, Wilhelm CR, Boyden AW, Karandikar NJ, Breheny P, Meyerholz DK, Dodd RD, Houtman JCD, Darbro BW, Quelle DE. Intratumoural plasma cells mediate a pro-inflammatory response to kinase inhibition and successful immune checkpoint blockade therapy in malignant peripheral nerve sheath tumours. EBioMedicine. 2026 Sep; 131:106413.
-
Tesch ME, Zheng Y, Guzman-Arocho YD, Collins LC, Heng YJ, Tayob N, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Peppercorn J, Borges V, Come SE, Snow C, Winer EP, Mittendorf EA, Partridge AH. Association of Tumor-Infiltrating Lymphocyte Subtypes with Clinical Characteristics and Prognosis in Young Women with Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2026 Jun 01; 32(11):2268-2278.
-
Nie Y, Staley A, Hinz TK, Perez-Johnston R, Merrick DT, Yang MC, Davies KD, Bunn PA, Aisner DL, Camidge DR, Schenk EL, Heasley LE, Patil T. High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors. Clin Lung Cancer. 2026 Jun; 27(5):96-105.
-
Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
-
Kantheti U, Shirley JL, Fry LG, Qvale AM, Olivas-Corral JG, Vankamamidi SE, Tamburini BAJ. PD-L1 cell-intrinsic signals limit immune activation during cutaneous vaccinia virus infection. J Immunol. 2026 Feb 09; 215(2).
-
Park JC, Berz D, Sharma MR, Malhotra J, Tolcher AW, Hauke RJ, Call JA, Hamm JT, Sanborn RE, Haas NB, Tsai F, Adkins DR, Camidge DR, Spira AI, Senne L, Kalabus J, O'Neill B, Kinkead H, Garcia J, Massarelli E. Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors. Cancer Res Commun. 2026 02 01; 6(2):374-382.
-
Yano H, Fujiwara Y, Mito R, Pan C, Ono K, Imamura K, Niidome T, Sawa T, Yamamoto M, Sakagami T, Komohara Y. Mycobacterium avium infection induced PD-L1 overexpression in macrophages: a potential involvement with immune escape. Cell Death Dis. 2026 Jan 09; 17(1):15.
-
Lu T, Hamidi H, Socinski MA, Reck M, Cappuzzo F, Barlesi F, Jotte RM, Müller S, Qamra A, Amitai A, Guan X, Fuentes E, Koeppen H, Giltnane JM, Shames DS, Ballinger M, He MX, Wang Y, Srivastava MK, Nabet BY. Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations. Nat Commun. 2025 12 03; 17(1):122.
-
Bar J, Cai MH, Choi YC, Baijal S, Zhao W, Liede A, Vasilopoulos A, Roberts-Rapp L, Jiang F, Simmons A, Ratajczak C, Lu S, Ansell PJ, Camidge DR. Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer. Acta Oncol. 2025 11 18; 64:1544-1553.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|